In Brief This Week: Foundation Medicine, Illumina; Thermo Fisher Scientific; RUCDR Infinite Biologics, NuGen; More | GenomeWeb

NEW YORK (GenomeWeb News) – Foundation Medicine's supply, service, and support agreement with Illumina inked in July is for five years and approximately $6.1 million, the Cambridge, Mass.-based firm said in an amended Form S-1 filed this week. The company originally disclosed the deal with Illumina in its Form S-1 filed in July in preparation of its initial public offering, but did not reveal the terms. Foundation plans to offer up to $86.3 million in its IPO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.